ArticleAnnals of hematology2026

Successful treatment of relapsed FLT3-mutated donor cell-derived MDS/AML with FLT3 inhibitor gilteritinib.

Mana Kawano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.